Internal Reference Number: FOI_9076
Date Request Received: 02/12/2025 00:00:00
Date Request Replied To: 17/12/2025 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 4 months (August to November 2025) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab | |
| Answer To Question 1: Please see our response to this FOI in the Excel spreadsheet attached To accompany this answer to question 1 please also see the documents listed below:  13386 - FOI_9076- Atopic Dermatitis.xlsx | |
| Question Number 2: In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab *Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen | |
| Answer To Question 2: Please see our response to this FOI in the Excel spreadsheet attached | |
| Question Number 3: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 3: Please see our response to this FOI in the Excel spreadsheet attached | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
